Skip to main content

Table 5 Results: LY and QALY (3% discount)

From: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

Parameter

Prophylaxis

Non prophylaxis

Difference

LY

   

Total

29.842

29.754

0.088

- BPD

29.813

29.694

0.119

- < 33 weeks

29.849

29.771

0.078

- 33–35 weeks

29.854

29.776

0.078

QALY

   

Total

29.202

29.043

0.159

- BPD

29.173

28.985

0.188

- < 33 weeks.

29.209

29.060

0.150

- 33–35 weeks

29.214

29.065

0.149